Claims

1. The meglumine salt of enantiomer A of 7-chloro-4-(2-oxo-1-phenyl-3-pyrrolidinylidene)-1,2,3,4-tetrahydro-2-quinolinecarboxylic acid.

2. A crystalline form of the compound as claimed in Claim 1.

3. The crystalline form described in Example 1.

4. A process for the preparation of the compound claimed in any of the claims 1 to 3 which comprises mixing enantiomer A of 7-chloro-4-(2-oxo-1-phenyl-3-pyrrolidinylidene)-1,2,3,4-tetrahydro-2-quinolinecarboxylic acid with meglumine in a suitable solvent.

5. A process for the preparation of a crystalline form as claimed in claim 2 or 3 which comprises crystallising the meglumine salt from a mixture of water and a water miscible organic solvent or from a mixture of siutable organic solvents..

6. A pharmaceutical composition comprising a compound as claimed in any of claims 1 to 3 in admixture with one or more physiologically acceptable carriers or excipients.

7. Use of a compound as claimed in any claims from 1 to 3 as medicine for antagonising the effects of excitatory amino acids upon the NMDA receptor complex.

8. A method of treatment of a mammal including man for conditions where antagonising the effects of excitatory amino acids on the NMDA receptor complex is of therapeutic benefit, comprising administration of an effective amount of a compound as claimed in any of claims 1 to 3.